No SEVI-mediated enhancement of rectal HIV-1 transmission of HIV-1 in two humanized mouse cohorts

Virology

Volumn 488, Issue , 2016, Pages 88-95

  Dis, Erik S Van ^a   Moore, Tyler C ^a   Lavender, Kerry J ^a   Messer, Ronald J ^a   Keppler, Oliver T ^b   Verheyen, Jens ^c   Dittmer, Ulf ^c   Hasenkrug, Kim J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Amyloid; HIV; Humanized mice; Semen derived enhancer of viral infection; SEVI; Transmission

Indexed keywords

AMYLOID; PEPTIDE; SEMEN DERIVED PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECTUM; T CELL DEPLETION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DISEASE MODEL; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; METABOLISM; SCID MOUSE; SPERM; TRANSMISSION; VIROLOGY;

AMYLOID; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MICE, INBRED C57BL; MICE, SCID; RECTUM; SEMEN;

EID: 84947765524     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.11.005     Document Type: Article

References (34)

1. Arnold F., Schnell J., Zirafi O., Sturzel C., Meier C., Weil T., Standker L., Forssmann W.G., Roan N.R., Greene W.C., Kirchhoff F., Munch J. Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. J. Virol. 2012, 86:1244-1249.
2. Cann A.J., Zack J.A., Go A.S., Arrigo S.J., Koyanagi Y., Green P.L., Koyanagi Y., Pang S., Chen I.S. Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J. Virol. 1990, 64:4735-4742.
3. Capule C.C., Brown C., Olsen J.S., Dewhurst S., Yang J. Oligovalent amyloid-binding agents reduce SEVI-mediated enhancement of HIV-1 infection. J. Am. Chem. Soc. 2012, 134:905-908.
4. Cornetta K., Anderson W.F. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. J. Virol. Methods 1989, 23:187-194.
5. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M., Wherry E.J., Coovadia H.M., Goulder P.J., Klenerman P., Ahmed R., Freeman G.J., Walker B.D. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
6. Deeks S.G., Kitchen C.M., Liu L., Guo H., Gascon R., Narvaez A.B., Hunt P., Martin J.N., Kahn J.O., Levy J., McGrath M.S., Hecht F.M. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004, 104:942-947.
7. Dimitrov D.S., Willey R.L., Sato H., Chang L.J., Blumenthal R., Martin M.A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 1993, 67:2182-2190.
8. Dyer J.R., Gilliam B.L., Eron J.J., Grosso L., Cohen M.S., Fiscus S.A. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J. Virol. Methods 1996, 60:161-170.
9. Giorgi J.V., Hultin L.E., McKeating J.A., Johnson T.D., Owens B., Jacobson L.P., Shih R., Lewis J., Wiley D.J., Phair J.P., Wolinsky S.M., Detels R. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 1999, 179:859-870.
10. Hauber I., Hohenberg H., Holstermann B., Hunstein W., Hauber J. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc. Natl. Acad. Sci. USA 2009, 106:9033-9038.
11. Hofer U., Baenziger S., Heikenwalder M., Schlaepfer E., Gehre N., Regenass S., Brunner T., Speck R.F. RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus. J. Virol. 2008, 82:12145-12153.
12. Kim K.A., Yolamanova M., Zirafi O., Roan N.R., Staendker L., Forssmann W.G., Burgener A., Dejucq-Rainsford N., Hahn B.H., Shaw G.M., Greene W.C., Kirchhoff F., Munch J. Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology 2010, 7:55.
13. Koyanagi Y., Miles S., Mitsuyasu R.T., Merrill J.E., Vinters H.V., Chen I.S. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 1987, 236:819-822.
14. Kutsch O., Benveniste E.N., Shaw G.M., Levy D.N. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J. Virol. 2002, 76:8776-8786.
15. Lavender K.J., Messer R.J., Race B., Hasenkrug K.J. Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(-/-)gammac(-/-)CD47(-/-) background. J. Immunol. Methods 2014, 407:127-134.
16. Lavender K.J., Pang W.W., Messer R.J., Duley A.K., Race B., Phillips K., Scott D., Peterson K.E., Chan C.K., Dittmer U., Dudek T., Allen T.M., Weissman I.L., Hasenkrug K.J. BLT-humanized C57BL/6 Rag2-/-gammac-/-CD47-/- mice are resistant to GVHD and develop B and T cell immunity to HIV infection. Blood 2013, 122:4013-40120.
17. Levy D.N., Aldrovandi G.M., Kutsch O., Shaw G.M. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. USA 2004, 101:4204-4209.
18. Manning J.S., Hackett A.J., Darby N.B. Effect of polycations on sensitivity of BALD-3T3 cells to murine leukemia and sarcoma virus infectivity. Appl Microbiol. 1971, 22:1162-1163.
19. Margolick J.B., Gange S.J., Detels R., O'Gorman M.R., Rinaldo C.R., Lai S. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 2006, 42:620-626.
20. Martellini J.A., Cole A.L., Svoboda P., Stuchlik O., Chen L.M., Chai K.X., Gangrade B.K., Sorensen O.E., Pohl J., Cole A.M. HIV-1 enhancing effect of prostatic acid phosphatase peptides is reduced in human seminal plasma. PLoS One 2011, 6:e16285.
21. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Barbas C.F., Burton D.R., Ho D.D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 1995, 69:101-109.
22. Munch J., Rucker E., Standker L., Adermann K., Goffinet C., Schindler M., Wildum S., Chinnadurai R., Rajan D., Specht A., Gimenez-Gallego G., Sanchez P.C., Fowler D.M., Koulov A., Kelly J.W., Mothes W., Grivel J.C., Margolis L., Keppler O.T., Forssmann W.G., Kirchhoff F. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007, 131:1059-1071.
23. Munch J., Sauermann U., Yolamanova M., Raue K., Stahl-Hennig C., Kirchhoff F. Effect of semen and seminal amyloid on vaginal transmission of simian immunodeficiency virus. Retrovirology 2013, 10:148.
24. Munch J., Standker L., Pohlmann S., Baribaud F., Papkalla A., Rosorius O., Stauber R., Sass G., Heveker N., Adermann K., Escher S., Kluver E., Doms R.W., Forssmann W.G., Kirchhoff F. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages. Antimicrob. Agents Chemother. 2002, 46:982-990.
25. Olsen J.S., Brown C., Capule C.C., Rubinshtein M., Doran T.M., Srivastava R.K., Feng C., Nilsson B.L., Yang J., Dewhurst S. Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. J. Biol. Chem. 2010, 285:35488-35496.
26. Orendi J.M., Bloem A.C., Borleffs J.C., Wijnholds F.J., de Vos N.M., Nottet H.S., Visser M.R., Snippe H., Verhoef J., Boucher C.A. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J. Infect. Dis. 1998, 178:1279-1287.
27. Roan N.R., Muller J.A., Liu H., Chu S., Arnold F., Sturzel C.M., Walther P., Dong M., Witkowska H.E., Kirchhoff F., Munch J., Greene W.C. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 2011, 10:541-550.
28. Roan N.R., Munch J., Arhel N., Mothes W., Neidleman J., Kobayashi A., Smith-McCune K., Kirchhoff F., Greene W.C. The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J. Virol. 2009, 83:73-80.
29. Roan N.R., Sowinski S., Munch J., Kirchhoff F., Greene W.C. Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J. Biol. Chem. 2010, 285:1861-1869.
30. Royce R.A., Sena A., Cates W., Cohen M.S. Sexual transmission of HIV. N. Engl. J. Med. 1997, 336:1072-1078.
31. Sheftic S.R., Snell J.M., Jha S., Alexandrescu A.T. Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper. Eur. Biophys. J. 2012, 41:695-704.
32. Sun Z., Denton P.W., Estes J.D., Othieno F.A., Wei B.L., Wege A.K., Melkus M.W., Padgett-Thomas A., Zupancic M., Haase A.T., Garcia J.V. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. 2007, 204:705-714.
33. Wang J.H., Janas A.M., Olson W.J., Wu L. Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. J. Virol. 2007, 81:8933-8943.
34. Wu L. Biology of HIV mucosal transmission. Curr. Opin. HIV AIDS 2008, 3:534-540.